LA JOLLA, Calif.,
At the same time Immunosyn announced the resignation of G.
"We appreciated David's expertise through this first leg of our development and welcome Douglas A. McClain, Jr. back in his former role as CFO. In the interim we have initiated a candidate search for a permanent CFO," commented Stephen D. Ferrone, CEO and President of Immunosyn Corporation.
About Immunosyn Corporation
La Jolla, CA-headquartered Immunosyn Corporation
(OTC Bulletin Board: IMYN) plans to market and distribute life enhancing
therapeutics. Currently, the company has exclusive worldwide rights from its
largest shareholder, Argyll Biotechnologies, LLC, to market, sell and
distribute SF-1019, a compound that was developed from extensive research into
Biological Response Modifiers (BRMs). Argyll Biotechnologies, LLC has
initiated the process for regulatory approval of SF-1019 in several countries
and preparations for clinical trials are underway in both the US and
Except for the historical information contained herein, this press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any forward-looking statements speak only as of the date on which such statements are made and involve risks and uncertainties detailed in the Company's filings with the Securities and Exchange commission, including risks summarized in the company's annual Report of form 10-K for its most recent fiscal year. The Company's actual results could differ materially from such forward-looking statements. The Company undertakes no obligation to update any forward-looking statement or statements to reflect new events or circumstances or future developments.
SOURCE Immunosyn Corporation